	US 12,448,439 B2
	Interferon beta antibodies and uses thereof
Stefano V. Gulla, Boston, MA (US); Christine Huard, Somerville, MA (US); Janet Elizabeth Buhlmann, Brookline, MA (US); Juan Carlos Almagro, Cambridge, MA (US); Sreekumar R. Kodangattil, Lexington, MA (US); Steven A. Greenberg, Newton, MA (US); Edward Roland Lavallie, Harvard, MA (US); Eric M. Bennett, Arlington, MA (US); Lidia Mosyak, Newton, MA (US); James Perry Hall, Stow, MA (US); and Anthony John Coyle, Boston, MA (US)
Assigned to PFIZER INC., New York, NY (US); and The Brigham and Women's Hospital, Inc., Boston, MA (US)
Filed by PFIZER INC., New York, NY (US); and The Brigham and Women's Hospital, Inc., Boston, MA (US)
Filed on Nov. 16, 2023, as Appl. No. 18/511,744.
Application 18/511,744 is a division of application No. 17/092,998, filed on Nov. 9, 2020, granted, now 11,858,986.
Application 17/092,998 is a division of application No. 15/581,079, filed on Apr. 28, 2017, granted, now 10,829,553, issued on Nov. 10, 2020.
Claims priority of provisional application 62/483,669, filed on Apr. 10, 2017.
Claims priority of provisional application 62/339,709, filed on May 20, 2016.
Claims priority of provisional application 62/329,327, filed on Apr. 29, 2016.
Prior Publication US 2024/0174742 A1, May 30, 2024
Int. Cl. C07K 16/24 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/249 (2013.01) [A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

9 Claims

1. A method of treating a disease, disorder, or condition, in which increased activity of IFNβ is pathogenic, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of the antibody, or antigen-binding fragment thereof, that specifically binds human IFNβ, wherein the antibody or antigen-binding fragment comprises (a) the CDR-H1, CDR-H2, and CDR-H3 sequences of SEQ ID NO: 28, and (b)

i) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 2;

ii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 3;

iii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 4;

iv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 5;

v) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 6;

vi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 7;

vii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 8;

viii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 9;

ix) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 10;

x) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 11;

xi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 12;

xii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 13;

xiii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 14;

xiv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 15;

xv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 16;

xvi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 17;

xvii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 18;

xviii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 19;

xix) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 20;

xx) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 21;

xxi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 22;

xxii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 23;

xxiii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 24;

xxiv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 25;

XXV) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 26;

xxvi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 27; or

xxvii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 1;

or a pharmaceutical composition comprising the antibody or antigen-binding fragment; wherein the disease, disorder, or condition, in which increased activity of IFNβ is pathogenic, is dermatomyositis (DM).